SCHEMBL10136874

SCHEMBL10136874

Cc1ccc2c(c1)N(CCCN1CCN(CCCN)CC1)c1ccccc1S2

nearest known ligand 0.64

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM1A O60341 8/20 0.64
HTR1A P08908 5/20 0.63
ADRA2A P08913 5/20 0.63
DRD2 P14416 5/20 0.63
ADRA2C P18825 5/20 0.63
SLC6A2 P23975 5/20 0.63
HTR2A P28223 5/20 0.63
SLC6A4 P31645 5/20 0.63
ADRA1A P35348 5/20 0.63
HRH1 P35367 5/20 0.63
DRD3 P35462 5/20 0.63
SLC6A3 Q01959 5/20 0.63
KCNH2 Q12809 5/20 0.63
LMNA P02545 4/20 0.63
TP53 P04637 4/20 0.63
CYP3A4 P08684 4/20 0.63
MAPT P10636 4/20 0.63
MAPK1 P28482 4/20 0.63
SMN1; SMN2 Q16637 4/20 0.63
ADRA2B P18089 4/20 0.63

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2615404 0.90 KDM1A (0.80) KDM1AHTR1AADRA2ADRD2ADRA2C
SCHEMBL10136833 0.90 KDM1A (0.61) KDM1AHTR1AADRA2ADRD2ADRA2C
SCHEMBL26002746 0.89 KDM1A (0.81) KDM1AHTR1AADRA2ADRD2ADRA2C
SCHEMBL25513974 0.89 KDM1A (0.68) KDM1AHTR1AADRA2ADRD2ADRA2C
SCHEMBL10136921 0.88 DRD3 (0.58) KDM1AHTR1AADRA2ADRD2ADRA2C
SCHEMBL2615383 0.88 LMNA (0.75) KDM1AHTR1AADRA2ADRD2ADRA2C
SCHEMBL13400183 0.86 KDM1A (0.69) KDM1AHTR1AADRA2ADRD2ADRA2C
SCHEMBL10136870 0.86 KDM1A (0.62) KDM1AHTR1AADRA2ADRD2ADRA2C
SCHEMBL20425942 0.86 KDM1A (0.62) KDM1AHTR1AADRA2ADRD2ADRA2C
SCHEMBL20425955 0.86 KDM1A (0.65) KDM1AHTR1AADRA2ADRD2ADRA2C

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120035161-A1 Novel Compositions and Methods of Treating Diseases Using the Same CORRIDOR PHARMACEUTICALS, INC. 2012-02-09 US disclosed
WO-2010009332-A1 BINDING AND INHIBITING 5-HT4 RECEPTOR IMMUNE CONTROL, INC. (US) 2010-01-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120035161-A1 Novel Compositions and Methods of Treating Diseases Using the Same NFATC1, BAX, BCL2 KDM1A 1810/4885HTR1A 3332/4885ADRA2A 2305/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.